Actor portrayal of a family engaging in conversation at their daughter's graduation

VYNDAMAX helps people with transthyretin cardiac amyloidosis (ATTR-CM) live longer

  • VYNDAMAX* was studied in the “Tafamidis in Transthyretin Amyloidosis Cardiomyopathy Clinical Trial” (known as ATTR-ACT)
  • The study tested if VYNDAMAX could help people with ATTR-CM live longer and reduce hospitalizations due to heart problems compared to placebo
  • The study also tested the impact of VYNDAMAX on quality of life and ability to function

*The clinical studies of VYNDAQEL® (a different form of tafamidis) supported the approval of VYNDAMAX. Both drugs contain the same active ingredient.

How was VYNDAMAX studied?

The safety and efficacy of VYNDAMAX were studied in a 30-month clinical study of 441 adult patients with wild-type or hereditary ATTR-CM.

  • The VYNDAMAX study primarily focused on the reduction of death and heart-related hospitalizations, as well as safety
  • VYNDAMAX was also assessed on other aspects of ATTR-CM, including walking distance (6-Minute Walk Test) and health-related quality of life
  • Efficacy and safety were determined by comparing patients treated with VYNDAMAX (n=264), with patients who did not take VYNDAMAX (placebo) (n=177)
  • Patients were evaluated every 6 months for a total of 30 months
VYNDAMAX was proven to help people live longer

 

Survival rate at month 30

71% and 57%, used to compare VYNDAMAX (tafamidis) survival rate at month 30 for people on treatment and those on a placebo. See safety info.

AFTER 21/2YEARS

more people were alive taking VYNDAMAX than placebo

VYNDAMAX was proven to reduce hospitalizations for heart problems

 

  • In the study, patients taking VYNDAMAX had fewer heart-related hospitalizations than those in the placebo group

32% LOWER RISK
of hospitalizations related to heart problems

Ambulance in a downward pointing arrow used to communicate that the people that took VYNDAMAX (tafamidis) had 32% lower risk of heart related hospitalizations. See safety info.

Health-related quality-of-life measures†

In a 2.5-year clinical study, compared to those not on treatment (placebo group), people taking VYNDAMAX reported:

Checkmark icon

Better quality of life

(mental health status, enjoyment of life)

Checkmark icon

Fewer heart-related symptoms

(shortness of breath, fatigue, swollen feet or ankles)

Checkmark icon

More comfort performing daily activities

(ability to perform social and physical activities)

†At the end of the 30-month study compared to people taking a placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to measure health-related quality of life. Patients in the VYNDAMAX and placebo groups had worse KCCQ overall summary scores at month 30 than at the start of the study.

importantWhile there's no cure today, VYNDAMAX slows down ATTR-CM so you can show up for what matters most

 

Remember that even if you don’t feel it working, always take VYNDAMAX as prescribed. It’s important to tell your doctor how you are feeling.

 

Heart function and exercise capacity were measured in patients taking VYNDAMAX

The 6-Minute Walk Test (6MWT) measured heart function and exercise capacity.

At 30 months, people who took VYNDAMAX were able to walk a significant 83 yards farther (almost the length of a football field) on average than people who did not take VYNDAMAX (placebo).‡

Illustration depicting the 6 minute walk test, at the end of the clinical trial, people who took VYNDAMAX (tafamidis) were able to walk 83 yards more on average than people who took placebo. See safety info.‡Patients in the VYNDAMAX and placebo groups had worse 6-minute walking distance than at the start of the study.

Watch how VYNDAMAX can help you

Create a discussion guide to help you log your symptoms and talk to your doctor about ATTR-CM

Get started
CARDIOLOGIST RECOMMENDED

VYNDAMAX is a treatment with a Class 1§ recommendation for ATTR-CM in guidelines from:

  • American College of Cardiology
  • American Heart Association
  • Heart Failure Society of America

§Class 1 guidelines are given when there’s strong evidence or general agreement that a treatment is beneficial, useful, and effective. The above recommendation is from the 2022 guidelines.

Explore how VYNDAMAX works